指南与共识脊柱关节炎

ASAS-EULAR 中轴型脊柱关节炎管理推荐:2022 年更新

ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update.
指南 / 共识 · Ann Rheum Dis · 2022-10-21

该更新遵循 EULAR 标准化操作流程,通过两项系统文献综述和专责小组会议讨论投票,形成 5 条总体原则和 15 条推荐。推荐涵盖治疗目标与监测、非药物治疗、NSAIDs 作为首选药物治疗、生物制剂及靶向合成 DMARDs 的启用条件、关节外表现的处理、治疗失败后的再评估与换药、持续缓解者的减量以及手术与脊柱骨折。

要点

  • 活动性 axSpA 患者若 ASDAS≥2.1 且 ≥2 种 NSAIDs 治疗失败,并具备 CRP 升高、骶髂关节 MRI 炎症或放射学骶髂关节炎之一,应考虑 bDMARDs 或 tsDMARDs。
  • 当前实践是开始 TNFi 或 IL-17i 治疗。
  • 反复葡萄膜炎或炎症性肠病优选 TNF 单克隆抗体,显著银屑病优选 IL-17i。

核心结论

  • 2022 年 ASAS-EULAR 推荐为中轴型脊柱关节炎患者的管理提供了最新指导。

研究设计与样本

  • 遵循 EULAR 标准化操作流程,开展了两项关于 axSpA 非药物和药物治疗的系统文献综述。
  • 在专责小组会议上呈现并讨论证据,更新总体原则和推荐后进行投票。

主要发现

  • 达成 5 条总体原则和 15 条推荐,聚焦个体化医疗;其中 8 条与既往推荐保持不变,3 条仅对命名做小幅编辑,2 条有相关更新(第 9、12 条),2 条为新制定(第 10、11 条)。
  • 前 5 条推荐关注治疗目标与监测、非药物治疗以及 NSAIDs 作为首选药物治疗。
  • 第 6-8 条推荐涉及镇痛药,不鼓励长期使用糖皮质激素和传统合成 DMARDs 治疗纯中轴受累。
  • 第 9 条推荐描述生物 DMARDs(即 TNFi、IL-17i)和靶向合成 DMARDs(即 JAK 抑制剂)用于 ASDAS≥2.1 且 ≥2 种 NSAIDs 治疗失败、并具备 CRP 升高、骶髂关节 MRI 炎症或放射学骶髂关节炎之一患者的指征;当前实践是开始 TNFi 或 IL-17i。
  • 第 10 条推荐涉及关节外表现,反复葡萄膜炎或炎症性肠病优选 TNF 单克隆抗体,显著银屑病优选 IL-17i;第 11 条推荐治疗失败时应重新评估诊断并考虑合并症的存在;第 12 条推荐确认活动性 axSpA 时换用另一种 b/tsDMARD;第 13 条推荐持续缓解患者可考虑减量而非立即停用 bDMARD;第 14、15 条推荐涉及手术和脊柱骨折。

关键数值与推荐

  • 第 9 条推荐:ASDAS≥2.1 且 ≥2 种 NSAIDs 治疗失败,并具备 CRP 升高、骶髂关节 MRI 炎症或放射学骶髂关节炎之一的活动性 axSpA 患者,应考虑 bDMARDs 或 tsDMARDs;当前实践是开始 TNFi 或 IL-17i。
  • 第 10 条推荐:反复葡萄膜炎或炎症性肠病优选 TNF 单克隆抗体,显著银屑病优选 IL-17i。
  • 第 13 条推荐:持续缓解患者可考虑 bDMARD 减量而非立即停药。

临床怎么用

  • 活动性 axSpA 患者若 ASDAS≥2.1 且 ≥2 种 NSAIDs 治疗失败,并具备 CRP 升高、骶髂关节 MRI 炎症或放射学骶髂关节炎之一,当前实践是开始 TNFi 或 IL-17i。
  • 反复葡萄膜炎或炎症性肠病患者优选 TNF 单克隆抗体,显著银屑病患者优选 IL-17i。
  • 治疗失败时应重新评估诊断并考虑合并症的存在;确认活动性 axSpA 时推荐换用另一种 b/tsDMARD。
  • 持续缓解患者可考虑 bDMARD 减量而非立即停药。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for the management of axial spondyloarthritis (axSpA). METHODS: Following the EULAR Standardised Operating Procedures, two systematic literature reviews were conducted on non-pharmacological and pharmacological treatment of axSpA. In a task force meeting, the evidence was presented, discussed, and overarching principles and recommendations were updated, followed by voting. RESULTS: Five overarching principles and 15 recommendations with a focus on personalised medicine were agreed: eight remained unchanged from the previous recommendations; three with minor edits on nomenclature; two with relevant updates (#9, 12); two newly formulated (#10, 11). The first five recommendations focus on treatment target and monitoring, non-pharmacological management and non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice pharmacological treatment. Recommendations 6-8 deal with analgesics and discourage long-term glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for pure axial involvement. Recommendation 9 describes the indication of biological DMARDs (bDMARDs, that is, tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i)) and targeted synthetic DMARDs (tsDMARDs, ie, Janus kinase inhibitors) for patients who have Ankylosing Spondylitis Disease Activity Score ≥2.1 and failed ≥2 NSAIDs and also have either elevated C reactive protein, MRI inflammation of sacroiliac joints or radiographic sacroiliitis. Current practice is to start a TNFi or IL-17i. Recommendation 10 addresses extramusculoskeletal manifestations with TNF monoclonal antibodies preferred for recurrent uveitis or inflammatory bowel disease, and IL-17i for significant psoriasis. Treatment failure should prompt re-evaluation of the diagnosis and consideration of the presence of comorbidities (#11). If active axSpA is confirmed, switching to another b/tsDMARD is recommended (#12). Tapering, rather than immediate discontinuation of a bDMARD, can be considered in patients in sustained remission (#13). The last recommendations (#14, 15) deal with surgery and spinal fractures. CONCLUSIONS: The 2022 ASAS-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ramiro S, Nikiphorou E, Sepriano A, et al. ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis. 2022. PMID: 36270658. doi:10.1136/ard-2022-223296

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。